By James Jorgenson (MS, RPh, FASHP) and Anthony Zappa (PharmD, MBA)

With continued interest in the US drug spend, the evolution of fully transparent PBM programs has introduced an alternative approach to traditional PBM structures aimed at enhanced utilization and cost controls.

To see this article, use this link.

Share this on Twitter: